However, specific chemotherapy regimens, epidermal-growth-factor receptor tyrosine-kinase inhibitors (EGFR-TKI) and anti-vascular endothelial growth factor (anti-VEGF) were not significantly associated with OS in patients with stage IV lung cancer (Table 3). Here, EGFR is linked to lung cancer.